Literature DB >> 2107599

Receptor-mediated endocytosis of tissue-type plasminogen activator (t-PA) by liver cells.

D C Rijken1, M Otter, J Kuiper, T J van Berkel.   

Abstract

Tissue-type plasminogen activator (t-PA) has a short half-life in the circulation because the enzyme is rapidly cleared by the liver. This short review summarizes recent literature concerning mechanisms of uptake and degradation of t-PA in the liver. In vivo studies in rats show that degradation takes place via a lysosomal pathway. Saturation of the uptake system at high t-PA concentrations suggests a receptor-mediated mechanism. Competition experiments with various glycoproteins indicate that the asialoglycoprotein receptor is not involved, but they point to a role for the mannose receptor, which recognizes t-PA via its high mannose-type oligosaccharide on the first kringle domain. Both in vivo and in vitro studies with isolated liver cells demonstrate that parenchymal cells, as well as liver endothelial cells, are involved in the clearance of t-PA. Parenchymal cells, as the hepatoma cell line Hep G2, endocytose t-PA via a still unknown, possibly t-PA specific receptor, while liver endothelial cells catabolize t-PA via the mannose receptor.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2107599     DOI: 10.1016/0049-3848(90)90379-q

Source DB:  PubMed          Journal:  Thromb Res Suppl        ISSN: 0896-0569


  12 in total

1.  Tissue plasminogen activator therapy for the eye.

Authors:  R C Tripathi; B J Tripathi
Journal:  Br J Ophthalmol       Date:  2005-11       Impact factor: 4.638

Review 2.  The plasminogen activator/plasmin system.

Authors:  J D Vassalli; A P Sappino; D Belin
Journal:  J Clin Invest       Date:  1991-10       Impact factor: 14.808

3.  Endocytosis and intracellular processing of tissue-type plasminogen activator by rat liver cells in vivo.

Authors:  E Stang; J Krause; W Seydel; T Berg; N Roos
Journal:  Biochem J       Date:  1992-03-15       Impact factor: 3.857

4.  The secreted form of dengue virus nonstructural protein NS1 is endocytosed by hepatocytes and accumulates in late endosomes: implications for viral infectivity.

Authors:  Sophie Alcon-LePoder; Marie-Thérèse Drouet; Pascal Roux; Marie-Pascale Frenkiel; Michel Arborio; Anne-Marie Durand-Schneider; Michèle Maurice; Isabelle Le Blanc; Jean Gruenberg; Marie Flamand
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

5.  A novel pseudopodial component of the dendritic cell anti-fungal response: the fungipod.

Authors:  Aaron K Neumann; Ken Jacobson
Journal:  PLoS Pathog       Date:  2010-02-12       Impact factor: 6.823

6.  Pharmacokinetic and thrombolytic properties of unglycosylated recombinant tissue-type plasminogen activator (BM 06.021) produced in Escherichia coli.

Authors:  U Martin; S Fischer; U Kohnert; U Opitz; R Rudolph; G Sponer; A Stern; K Strein
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-07       Impact factor: 3.000

7.  Evidence for carbohydrate-independent endocytosis of tissue-type plasminogen activator by liver cells.

Authors:  E Stang; N Roos; M Schlüter; T Berg; J Krause
Journal:  Biochem J       Date:  1992-08-01       Impact factor: 3.857

8.  Characterization of the interaction both in vitro and in vivo of tissue-type plasminogen activator (t-PA) with rat liver cells. Effects of monoclonal antibodies to t-PA.

Authors:  M Otter; J Kuiper; R Bos; D C Rijken; T J van Berkel
Journal:  Biochem J       Date:  1992-06-01       Impact factor: 3.857

9.  Complexes of tissue-type plasminogen activator and its serpin inhibitor plasminogen-activator inhibitor type 1 are internalized by means of the low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor.

Authors:  K Orth; E L Madison; M J Gething; J F Sambrook; J Herz
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

10.  Scale up and pharmacokinetic study of a novel mutated chimeric tissue plasminogen activator (mt-PA) in rats.

Authors:  Mozhgan Raigani; Mohammad-Reza Rouini; Ali-Akbar Golabchifar; Esmat Mirabzadeh; Behrouz Vaziri; Farzaneh Barkhordari; Fatemeh Davami; Fereidoun Mahboudi
Journal:  Sci Rep       Date:  2017-02-22       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.